Navepegritide: Advancing Achondroplasia Treatment Outcomes

This keynote will explore the groundbreaking advancements in treating achondroplasia with a focus on navepegritide, a prodrug of C-type natriuretic peptide. Key topics include the genetic basis and challenges of achondroplasia, the drug's innovative mechanism targeting FGFR3 signaling, and evidence from pivotal clinical trials such as ACcomplisH and ApproaCH. Emphasis will be placed on safety, efficacy, and quality of life improvements, underscoring the importance of comprehensive care and...